CTLA4 and melanoma: For instance, a meta-analysis revealed that in advanced melanoma treatment, discontinuation because of adverse events did not negatively influence treatment outcomes with anti-CTLA-4 and anti-PD-1, suggesting that shorter treatment duration does not necessarily compromise the therapeutic efficacy of ICPi [163].